Clinical trials recruiting for Biliary Tract Cancer
18
Recruiting trials
26
US states with sites
20
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Cisplatin | 4 |
| Gemcitabine | 3 |
| 5-Fluorouracil | 2 |
| Bevacizumab | 2 |
| Carboplatin | 2 |
| Nab-paclitaxel | 2 |
| AB122 | 1 |
| AB154 | 1 |
| AZD0901 | 1 |
| BL-M07D1 | 1 |
| CDH17 CAR-T | 1 |
| Capecitabine | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 9 |
| California | 7 |
| Massachusetts | 5 |
| New York | 5 |
| Florida | 3 |
| Michigan | 3 |
| Ohio | 3 |
| Tennessee | 3 |
| Virginia | 3 |
| Colorado | 2 |
| Georgia | 2 |
| Kentucky | 2 |
Top cities
Houston, Texas 7Boston, Massachusetts 5Los Angeles, California 5San Antonio, Texas 4Nashville, Tennessee 3Columbus, Ohio 2Commack, New York 2Grand Rapids, Michigan 2Madison, Wisconsin 2Miami, Florida 2
Self-screener
Recruiting trials
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- AB122 Platform Study
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
- Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
- Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
- HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
- This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Use of Ctdna in Patients With Gastrointestinal Tract Tumors
- Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Related conditions
Trials recruiting for Biliary Tract Cancer often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Colorectal cancer 1359Lung cancer 2180Gastric cancer 91Ovarian cancer 118Non-small cell lung cancer 507Endometrial cancer 68Breast cancer 2239Prostate cancer 1234Esophageal cancer 65
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Biliary Tract Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.